LEO Pharma Just Paid $435M for a Drug That Isn't Approved Yet

LEO's Dermatology Shopping Spree

This isn't a one-off purchase. LEO Pharma has been on a calculated buying and partnering spree for the past two years, quietly assembling one of the most focused rare-dermatology portfolios in the industry.

In 2024, LEO acquired TMB-001 for congenital ichthyosis (another rare skin disease) and pushed its chronic hand eczema drug delgocitinib toward launch. In January 2025, LEO struck a major strategic partnership with Gilead Sciences on an oral STAT6 program for inflammatory diseases, pulling in 1.8 billion Danish krone upfront (roughly $250 million) with potential total payments reaching 10.5 billion krone.

Then in July 2025, LEO took over commercialization of spesolimab (Spevigo) from Boehringer Ingelheim for generalized pustular psoriasis. And in April 2026, LEO announced the acquisition of a company called Replay.

See the pattern? LEO is stacking rare and hard-to-treat skin disease assets like a collector building a very specific, very expensive deck of cards. Dersimelagon is the latest addition, and it might be the most commercially promising one.

The Price Tag: Smart Bet or Overpay?

LEO itself tipped its hand on how seriously it takes this asset. After announcing the deal, the company raised its 2026 revenue growth guidance to 9–11% (from 8–11%) but simultaneously lowered its adjusted EBITDA margin outlook to 14–16% (from 15–18%). Translation: LEO expects to make more money eventually, but the near-term costs of pre-launch activities and 2027 launch preparation will eat into profits.

That's a classic "spend now, earn later" setup. The company is essentially telling the market to be patient.

Is $435 million a lot for an unapproved orphan drug? In a vacuum, sure. But dersimelagon has some powerful tailwinds. It carries both FDA Fast Track Designation (granted back in 2018) and Orphan Drug Designation (2020), which means seven years of market exclusivity in the U.S. after approval and a smoother regulatory path. For a rare disease with essentially no approved competition, that exclusivity is a golden ticket.

The drug also reported positive topline Phase 3 results in January 2026, with data presented at the American Academy of Dermatology meeting in March. It's not sitting in early-stage limbo; it's knocking on the FDA's door.

Why Tanabe Let It Go

Here's the part that might seem counterintuitive. If dersimelagon is so promising, why would Tanabe sell the worldwide rights?

The answer is infrastructure. Tanabe is a mid-sized Japanese pharma company. Launching an orphan dermatology drug globally requires specialized sales teams, payer relationships, and patient-finding capabilities that LEO has spent decades building. LEO already sells dermatology products across dozens of markets. Tanabe would have needed to build all of that from scratch, or find a partner who already had it.

Selling to LEO lets Tanabe pocket significant upfront cash plus royalties on every sale, without shouldering the enormous cost of a global commercial launch. It's the biotech equivalent of a songwriter selling their hit to a record label with better distribution: you give up some upside, but you guarantee the song actually gets heard.

The Bigger Picture

This deal signals something important about where the dermatology market is headed. The big-money action isn't just in blockbuster conditions like eczema and psoriasis anymore. Companies are racing into rare and ultra-rare skin diseases, where small patient populations meet high price points and long exclusivity windows.

LEO Pharma is betting its future on becoming the go-to company for skin diseases that most pharma giants consider too niche to bother with. Dersimelagon fits that thesis perfectly: a first-in-class oral drug for a disease with no real treatment options and a clear regulatory pathway.

The $435 million question is whether LEO can get it across the finish line and onto pharmacy shelves. If the FDA cooperates, 2027 could be the year that people with EPP finally get to step into the sunlight without fear. And LEO Pharma would own the only ticket in town.

Amylyx's Unlikely Comeback Started With a Sugar Crash

Amylyx was left for dead after its ALS drug imploded. Two years later, a $35 million acquisition just delivered Phase 3 data so strong it could create the first approved treatment for a post-surgical complication nobody's been able to fix.